Abstract

Hajera Unnisa*, Dr. Maryam, Dr. Syed Ibrahim Hassan, Amreena Shahista, Huda Tahera and Soofia Jabeen

ABSTRACT

Background: Functional dyspepsia (FD) is characterized by chronic digestive symptoms including postprandial fullness, early satiation, burning and discomfort in the stomach, bloating, nausea, vomiting, and belching. This study aims to evaluate the efficacy and safety of Acotiamide in treating Functional dyspepsia compared to proton pump inhibitors (PPIs), Flupentixol, and Melitracen in Non-Diabetic patients. Method: A prospective, comparative investigation was carried out for 6 months, enrolling 100 non-diabetic patients who were diagnosed with functional dyspepsia following Helicobacter Pylori eradication. Group 1 received Acotiamide while Group 2 was treated with PPI, Flupentixol, and Melitracen. Treatment effectiveness was assessed using the Hospital Anxiety and Depression Scale (HADS) and the Gastrointestinal Symptoms Rating Scale (GSRS). Results: Both the treatment groups demonstrated significant improvement in Gastrointestinal symptoms. Acotiamide was effective and well tolerated, with no serious side effects reported when compared to PPI with Flupentixol and Melitracen. Conclusion: Acotiamide is an effective and safe treatment for FD in non-diabetic patients, with comparable efficacy to the combination of rabeprazole, flupentixol, and melitracen. Acotiamide offers a well-tolerated alternative for managing FD symptoms without significant adverse effects.